Abstract:Background: Malignant pleural mesothelioma (MPM) is characterized by therapeutically intractable loss-of-function mutations of tumor suppressor genes. Identification of actionable targets for the effective treatment of MPM remains an unmet clinical need. Methods: We integrated multi-omics data from patient samples of The Cancer Genome Atlas and Gene Expression Omnibus to identify cellular processes that exhibit oncogenic dependencies and particularly therapeutic vulnerabilities in MPM. Functional and mechanistic studies were pursued by genetic and pharmacological perturbations. The anti-MPM activity of combined therapy with MEK- and PARP-targeted drugs were assessed in vitro and in vivo in various mouse models. Findings: We discovered that mitogen-activated protein kinase kinase 1 (MEK1) functions as a previously unrecognized oncogenic driver in MPM, independent of tumor histological and genetic heterogeneity. Nevertheless, the efficacy of MEK-targeted therapies as single agents in MPM is compromised by a protective mechanism that involves PARP1. Mechanistically, MEK inhibition unmasks latent defects in genetic and metabolic homeostasis that manifest by impaired DNA homologous recombination repair and bioenergetic stress in mitochondria, which could be simultaneously restored by PARP1. Consequently, the combination of clinically approved MEK and PARP inhibitors exacerbates DNA damage and metabolic dysfunction, leading to synergistically enhanced MPM cell death and retarded tumor growth.Interpretation: Our study uncovers a previously unrecognized oncogenic driver and provides mechanistic insights for a readily translatable therapeutic strategy for the treatment of refractory MPM.Funding Information: This work was supported by grants from the Swiss Cancer League/Swiss Cancer Research Foundation (#KFS-4851-08-2019; to R-W. Peng), Swiss National Science Foundation (SNSF; #310030_192648; to R-W. Peng), and PhD fellowships from the China Scholarship Council (to H. Yang, Y. Gao and Z. Yang).Declaration of Interests: The authors declare that they have no conflict of interest.Ethics Approval Statement: All human studies were performed under the auspices of protocols approved by the institutional review board (KEK number: 042/15 and 200/2014), and informed consent was obtained from all patients as per protocol. Mouse studies were conducted in accordance with animal guidelines and protocols approved by the Institutional Animal Care and Ethical Committee.

Metastasis-associated gene 1 (MTA1) enhances cisplatin resistance of malignant pleural mesothelioma by ATR-Chk1-mediated DNA repair

MTA1 Promotes Metastasis of MPM Via Suppression of E-cadherin

Research Progress on Molecular Mechanism Underlying Chemotherapy Resistance of Malignant Pleural Mesothelioma

MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring Craf-Independent MEK Activation.

Putative Cancer Stem Cells In Malignant Pleural Mesothelioma Show Resistance To Cisplatin And Pemetrexed

CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma.

WT1 mRNA Expression is a Good Laboratory Indicator for Diagnosis of Disease Progression in MDS Patients with Stable Disease

Simultaneous Targeting of ATM and Mcl-1 Increases Cisplatin Sensitivity of Cisplatin-Resistant Non-Small Cell Lung Cancer

Therapeutic Targeting of MEK1/2 Synergizes with PARP1 Inhibitors in the Treatment of Malignant Pleural Mesothelioma

Increased Sensitivity to Apoptosis Upon Endoplasmic Reticulum Stress-Induced Activation of the Unfolded Protein Response in Chemotherapy-Resistant Malignant Pleural Mesothelioma

MTA1 Promotes Tumorigenesis and Development of Esophageal Squamous Cell Carcinoma Via Activating the MEK/ERK/p90RSK Signaling Pathway

Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment

731 EVALUATION OF THE SELF-DESIGNED ULTRASONIC ATOMIZATION SPRAYING EQUIPMENT FOR INTRAVASCULAR STENTS

Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma.

Methyltransferase-like 3 upregulation is involved in the chemoresistance of non-small cell lung cancer

Metadherin Is a Prognostic Apoptosis Modulator in Mesothelioma Induced via NF-κB-Mediated Signaling.

The c-MYC transcription factor conduces to resistance to cisplatin by regulating MMS19 in bladder cancer cells

MEK1 Drives Oncogenic Signaling and Interacts with PARP1 for Genomic and Metabolic Homeostasis in Malignant Pleural Mesothelioma.

LncRNA-MALAT1 Mediates Cisplatin Resistance Via Mir-101-3p/vegf-c Pathway in Bladder Cancer.

MTA1 Coregulator Regulates P53 Stability and Function

MTA1, a Novel ATP Synthase Complex Modulator, Enhances Colon Cancer Liver Metastasis by Driving Mitochondrial Metabolism Reprogramming